Trial Profile
NWP06 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)- A Laboratory Classroom Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Aug 2014
Price :
$35
*
At a glance
- Drugs Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 01 Oct 2012 Primary endpoint 'SKAMP-rating-scale' has been met.
- 16 Dec 2009 New trial record